Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guérin Versus Gemcitabine in Treatment-Naïve Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis.

J Clin Med · 2026 · PMC13207305 · PMID 42194851

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significancep = 0.076so close (0.05 < p ≤ 0.1)

gemcitabine, 54.9%; SMD = 0.346), although this did not reach statistical significance ( p = 0.076).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.